PepsiCo CEO Ramon Laguarta mentioned the GLP-1 trend at the company's earnings announcement in February, saying he would expand smaller-portion products and pursue the development of products fortified with protein and dietary fiber
In this narrative review, we thoroughly trace the current preclinical and clinical evidence of seven pain modalities, including inflammatory pain, osteoarthritis, visceral pain, neuropathic pain, diabetic neuropathy, cancer pain and headache, to support the efficacy and underlying biological mechanisms of GLP-1RAs as therapeutic agents for pain suffering
Opportunities exist to develop drugs with a durable weight-loss effect in the absence of ongoing pharmacotherapy which would be greatly attractive to patients
Liang Z, Liu Y, Sun X, Lin J, Yao J, Song Y, et al